Tremendous advances have been made in the treatment of neovascular age-related macular degeneration (AMD) with the introduction of anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections [1,2,3]. This evidence concerns the gene VEGFA and age-related macular degeneration.